nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—HTR1B—artery—abdominal aortic aneurysm	0.0651	0.125	CbGeAlD
Atomoxetine—HTR1D—artery—abdominal aortic aneurysm	0.0631	0.121	CbGeAlD
Atomoxetine—HTR2A—hindlimb—abdominal aortic aneurysm	0.0511	0.0978	CbGeAlD
Atomoxetine—SLC6A4—blood plasma—abdominal aortic aneurysm	0.0444	0.085	CbGeAlD
Atomoxetine—CYP2C19—blood plasma—abdominal aortic aneurysm	0.0368	0.0704	CbGeAlD
Atomoxetine—HTR2A—artery—abdominal aortic aneurysm	0.0313	0.0599	CbGeAlD
Atomoxetine—HTR1D—connective tissue—abdominal aortic aneurysm	0.0252	0.0482	CbGeAlD
Atomoxetine—HTR2A—blood plasma—abdominal aortic aneurysm	0.0235	0.045	CbGeAlD
Atomoxetine—NPY1R—Peptide GPCRs—AGTR1—abdominal aortic aneurysm	0.0227	0.0475	CbGpPWpGaD
Atomoxetine—CYP3A4—blood plasma—abdominal aortic aneurysm	0.0218	0.0416	CbGeAlD
Atomoxetine—HTR1D—kidney—abdominal aortic aneurysm	0.0214	0.041	CbGeAlD
Atomoxetine—CYP2D6—blood plasma—abdominal aortic aneurysm	0.0214	0.041	CbGeAlD
Atomoxetine—HTR1B—spinal cord—abdominal aortic aneurysm	0.0173	0.033	CbGeAlD
Atomoxetine—SLC6A3—spinal cord—abdominal aortic aneurysm	0.0171	0.0327	CbGeAlD
Atomoxetine—HTR2C—spinal cord—abdominal aortic aneurysm	0.0165	0.0316	CbGeAlD
Atomoxetine—SLC6A4—spinal cord—abdominal aortic aneurysm	0.0157	0.03	CbGeAlD
Atomoxetine—NPY1R—G alpha (i) signalling events—P2RY12—abdominal aortic aneurysm	0.0148	0.031	CbGpPWpGaD
Atomoxetine—NPY1R—GPCRs, Class A Rhodopsin-like—P2RY12—abdominal aortic aneurysm	0.0137	0.0288	CbGpPWpGaD
Atomoxetine—HTR2A—connective tissue—abdominal aortic aneurysm	0.0125	0.0239	CbGeAlD
Atomoxetine—SLC6A4—Monoamine Transport—AGT—abdominal aortic aneurysm	0.0122	0.0256	CbGpPWpGaD
Atomoxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—P2RY12—abdominal aortic aneurysm	0.0118	0.0246	CbGpPWpGaD
Atomoxetine—NPY1R—Peptide ligand-binding receptors—AGTR1—abdominal aortic aneurysm	0.0107	0.0224	CbGpPWpGaD
Atomoxetine—HTR2A—kidney—abdominal aortic aneurysm	0.0107	0.0204	CbGeAlD
Atomoxetine—SLC6A2—Monoamine Transport—AGT—abdominal aortic aneurysm	0.0105	0.022	CbGpPWpGaD
Atomoxetine—CYP3A4—kidney—abdominal aortic aneurysm	0.00986	0.0189	CbGeAlD
Atomoxetine—CYP2D6—kidney—abdominal aortic aneurysm	0.00971	0.0186	CbGeAlD
Atomoxetine—SLC6A3—Monoamine Transport—AGT—abdominal aortic aneurysm	0.00932	0.0195	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR ligand binding—P2RY12—abdominal aortic aneurysm	0.00895	0.0188	CbGpPWpGaD
Atomoxetine—NPY1R—GPCRs, Class A Rhodopsin-like—AGTR1—abdominal aortic aneurysm	0.00835	0.0175	CbGpPWpGaD
Atomoxetine—HTR2A—spinal cord—abdominal aortic aneurysm	0.0083	0.0159	CbGeAlD
Atomoxetine—NPY1R—Peptide ligand-binding receptors—AGT—abdominal aortic aneurysm	0.00751	0.0157	CbGpPWpGaD
Atomoxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—AGTR1—abdominal aortic aneurysm	0.00716	0.015	CbGpPWpGaD
Atomoxetine—NPY1R—G alpha (i) signalling events—AGT—abdominal aortic aneurysm	0.00633	0.0133	CbGpPWpGaD
Atomoxetine—NPY1R—Peptide ligand-binding receptors—CCL2—abdominal aortic aneurysm	0.00618	0.013	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR ligand binding—AGTR1—abdominal aortic aneurysm	0.00545	0.0114	CbGpPWpGaD
Atomoxetine—HTR1D—G alpha (i) signalling events—P2RY12—abdominal aortic aneurysm	0.00541	0.0113	CbGpPWpGaD
Atomoxetine—HTR1B—G alpha (i) signalling events—P2RY12—abdominal aortic aneurysm	0.0053	0.0111	CbGpPWpGaD
Atomoxetine—HTR6—GPCRs, Class A Rhodopsin-like—P2RY12—abdominal aortic aneurysm	0.00506	0.0106	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—P2RY12—abdominal aortic aneurysm	0.00506	0.0106	CbGpPWpGaD
Atomoxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—AGT—abdominal aortic aneurysm	0.00504	0.0106	CbGpPWpGaD
Atomoxetine—CYP2C19—Melatonin metabolism and effects—APOE—abdominal aortic aneurysm	0.00503	0.0105	CbGpPWpGaD
Atomoxetine—HTR1D—GPCRs, Class A Rhodopsin-like—P2RY12—abdominal aortic aneurysm	0.00502	0.0105	CbGpPWpGaD
Atomoxetine—HTR1B—GPCRs, Class A Rhodopsin-like—P2RY12—abdominal aortic aneurysm	0.00492	0.0103	CbGpPWpGaD
Atomoxetine—CYP2D6—Melatonin metabolism and effects—APOE—abdominal aortic aneurysm	0.00463	0.0097	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—P2RY12—abdominal aortic aneurysm	0.0046	0.00963	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—P2RY12—abdominal aortic aneurysm	0.00434	0.00909	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—P2RY12—abdominal aortic aneurysm	0.0043	0.00902	CbGpPWpGaD
Atomoxetine—SLC6A2—SLC-mediated transmembrane transport—AAAS—abdominal aortic aneurysm	0.00427	0.00894	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—P2RY12—abdominal aortic aneurysm	0.00422	0.00883	CbGpPWpGaD
Atomoxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—CCL2—abdominal aortic aneurysm	0.00415	0.00869	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR ligand binding—AGT—abdominal aortic aneurysm	0.00383	0.00804	CbGpPWpGaD
Atomoxetine—SLC6A3—SLC-mediated transmembrane transport—AAAS—abdominal aortic aneurysm	0.00378	0.00792	CbGpPWpGaD
Atomoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—P2RY12—abdominal aortic aneurysm	0.00373	0.00781	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—P2RY12—abdominal aortic aneurysm	0.0033	0.00692	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—P2RY12—abdominal aortic aneurysm	0.00328	0.00687	CbGpPWpGaD
Atomoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—P2RY12—abdominal aortic aneurysm	0.00324	0.00678	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—P2RY12—abdominal aortic aneurysm	0.00321	0.00673	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—P2RY12—abdominal aortic aneurysm	0.00319	0.00669	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR ligand binding—CCL2—abdominal aortic aneurysm	0.00316	0.00662	CbGpPWpGaD
Atomoxetine—HTR6—GPCRs, Class A Rhodopsin-like—AGTR1—abdominal aortic aneurysm	0.00308	0.00646	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—AGTR1—abdominal aortic aneurysm	0.00308	0.00645	CbGpPWpGaD
Atomoxetine—HTR1D—GPCRs, Class A Rhodopsin-like—AGTR1—abdominal aortic aneurysm	0.00306	0.00641	CbGpPWpGaD
Atomoxetine—HTR1B—GPCRs, Class A Rhodopsin-like—AGTR1—abdominal aortic aneurysm	0.00299	0.00627	CbGpPWpGaD
Atomoxetine—CYP2C19—Melatonin metabolism and effects—NFKB1—abdominal aortic aneurysm	0.00299	0.00627	CbGpPWpGaD
Atomoxetine—HTR2C—G alpha (q) signalling events—AGTR1—abdominal aortic aneurysm	0.00294	0.00615	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—LRP1—abdominal aortic aneurysm	0.0029	0.00608	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—AGTR1—abdominal aortic aneurysm	0.0028	0.00586	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—P2RY12—abdominal aortic aneurysm	0.00277	0.00581	CbGpPWpGaD
Atomoxetine—CYP2D6—Melatonin metabolism and effects—NFKB1—abdominal aortic aneurysm	0.00275	0.00577	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—P2RY12—abdominal aortic aneurysm	0.00271	0.00569	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—AGTR1—abdominal aortic aneurysm	0.00264	0.00553	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—abdominal aortic aneurysm	0.00263	0.0055	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—AGTR1—abdominal aortic aneurysm	0.00262	0.00549	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—NOS2—abdominal aortic aneurysm	0.00257	0.00538	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—AGTR1—abdominal aortic aneurysm	0.00257	0.00537	CbGpPWpGaD
Atomoxetine—HTR2A—G alpha (q) signalling events—AGTR1—abdominal aortic aneurysm	0.00255	0.00534	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—MMP3—abdominal aortic aneurysm	0.00249	0.00522	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—P2RY12—abdominal aortic aneurysm	0.00243	0.0051	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—abdominal aortic aneurysm	0.00234	0.0049	CbGpPWpGaD
Atomoxetine—HTR1D—G alpha (i) signalling events—AGT—abdominal aortic aneurysm	0.00232	0.00486	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—abdominal aortic aneurysm	0.00228	0.00478	CbGpPWpGaD
Atomoxetine—HTR1B—G alpha (i) signalling events—AGT—abdominal aortic aneurysm	0.00227	0.00476	CbGpPWpGaD
Atomoxetine—HTR2C—GPCRs, Class A Rhodopsin-like—AGTR1—abdominal aortic aneurysm	0.00227	0.00475	CbGpPWpGaD
Atomoxetine—CYP2C19—Arachidonic acid metabolism—PTGS2—abdominal aortic aneurysm	0.00223	0.00467	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—LDLR—abdominal aortic aneurysm	0.0022	0.00461	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—AAAS—abdominal aortic aneurysm	0.00217	0.00454	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—AGT—abdominal aortic aneurysm	0.00217	0.00454	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—SERPINE1—abdominal aortic aneurysm	0.00216	0.00453	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—P2RY12—abdominal aortic aneurysm	0.00211	0.00443	CbGpPWpGaD
Atomoxetine—HTR2C—G alpha (q) signalling events—AGT—abdominal aortic aneurysm	0.00207	0.00433	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—NCF1—abdominal aortic aneurysm	0.00206	0.00431	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—abdominal aortic aneurysm	0.00203	0.00426	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—AGTR1—abdominal aortic aneurysm	0.00201	0.00421	CbGpPWpGaD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—NFKB1—abdominal aortic aneurysm	0.00201	0.00421	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—AGTR1—abdominal aortic aneurysm	0.00199	0.00418	CbGpPWpGaD
Atomoxetine—HTR2A—GPCRs, Class A Rhodopsin-like—AGTR1—abdominal aortic aneurysm	0.00197	0.00413	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—AGT—abdominal aortic aneurysm	0.00197	0.00412	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—AGTR1—abdominal aortic aneurysm	0.00195	0.00409	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—AGTR1—abdominal aortic aneurysm	0.00194	0.00407	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—AAAS—abdominal aortic aneurysm	0.00192	0.00402	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—P2RY12—abdominal aortic aneurysm	0.00187	0.00391	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—AGT—abdominal aortic aneurysm	0.00186	0.00389	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—P2RY12—abdominal aortic aneurysm	0.00185	0.00388	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—abdominal aortic aneurysm	0.00185	0.00387	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—AGT—abdominal aortic aneurysm	0.00184	0.00386	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—P2RY12—abdominal aortic aneurysm	0.00181	0.0038	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—AGT—abdominal aortic aneurysm	0.0018	0.00378	CbGpPWpGaD
Atomoxetine—HTR2A—G alpha (q) signalling events—AGT—abdominal aortic aneurysm	0.00179	0.00376	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—P2RY12—abdominal aortic aneurysm	0.0017	0.00355	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—AGTR1—abdominal aortic aneurysm	0.00169	0.00354	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—P2RY12—abdominal aortic aneurysm	0.00168	0.00353	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—AGTR1—abdominal aortic aneurysm	0.00165	0.00346	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—P2RY12—abdominal aortic aneurysm	0.00165	0.00345	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—CCL2—abdominal aortic aneurysm	0.00162	0.0034	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—abdominal aortic aneurysm	0.0016	0.00336	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CCL2—abdominal aortic aneurysm	0.00153	0.00321	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—CCL2—abdominal aortic aneurysm	0.00152	0.00318	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—CCL2—abdominal aortic aneurysm	0.00149	0.00311	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—AGTR1—abdominal aortic aneurysm	0.00148	0.0031	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—MMP3—abdominal aortic aneurysm	0.00147	0.00309	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—AGT—abdominal aortic aneurysm	0.00141	0.00296	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—AGT—abdominal aortic aneurysm	0.0014	0.00294	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—P2RY12—abdominal aortic aneurysm	0.00137	0.00288	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—AGT—abdominal aortic aneurysm	0.00137	0.00288	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—AGT—abdominal aortic aneurysm	0.00137	0.00287	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—AGTR1—abdominal aortic aneurysm	0.00129	0.00269	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—P2RY12—abdominal aortic aneurysm	0.00125	0.00262	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—NFKB1—abdominal aortic aneurysm	0.00121	0.00253	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—P2RY12—abdominal aortic aneurysm	0.00119	0.0025	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—AGT—abdominal aortic aneurysm	0.00119	0.00249	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—CCL2—abdominal aortic aneurysm	0.00116	0.00244	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—AGT—abdominal aortic aneurysm	0.00116	0.00244	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—CCL2—abdominal aortic aneurysm	0.00116	0.00242	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—APOE—abdominal aortic aneurysm	0.00114	0.00239	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—AGTR1—abdominal aortic aneurysm	0.00114	0.00238	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—CCL2—abdominal aortic aneurysm	0.00113	0.00237	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—AGTR1—abdominal aortic aneurysm	0.00113	0.00236	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCL2—abdominal aortic aneurysm	0.00113	0.00236	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—AGTR1—abdominal aortic aneurysm	0.0011	0.00231	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—P2RY12—abdominal aortic aneurysm	0.00108	0.00227	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—LRP1—abdominal aortic aneurysm	0.00107	0.00224	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—LRP1—abdominal aortic aneurysm	0.00106	0.00223	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—AGT—abdominal aortic aneurysm	0.00104	0.00218	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—LRP1—abdominal aortic aneurysm	0.00104	0.00218	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—AGTR1—abdominal aortic aneurysm	0.00103	0.00216	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—AGTR1—abdominal aortic aneurysm	0.00102	0.00215	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—AGTR1—abdominal aortic aneurysm	0.001	0.0021	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—P2RY12—abdominal aortic aneurysm	0.001	0.0021	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—P2RY12—abdominal aortic aneurysm	0.000994	0.00208	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCL2—abdominal aortic aneurysm	0.000978	0.00205	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—P2RY12—abdominal aortic aneurysm	0.000973	0.00204	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CCL2—abdominal aortic aneurysm	0.000957	0.00201	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—MMP3—abdominal aortic aneurysm	0.000919	0.00193	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—MMP3—abdominal aortic aneurysm	0.000912	0.00191	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—AGT—abdominal aortic aneurysm	0.000905	0.0019	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—LDLR—abdominal aortic aneurysm	0.000898	0.00188	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—SERPINE1—abdominal aortic aneurysm	0.000894	0.00187	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—MMP3—abdominal aortic aneurysm	0.000893	0.00187	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—CCL2—abdominal aortic aneurysm	0.000858	0.0018	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—AGTR1—abdominal aortic aneurysm	0.000837	0.00175	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—LDLR—abdominal aortic aneurysm	0.000811	0.0017	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—LDLR—abdominal aortic aneurysm	0.000805	0.00169	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—AGT—abdominal aortic aneurysm	0.000799	0.00168	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—AGT—abdominal aortic aneurysm	0.000793	0.00166	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—LDLR—abdominal aortic aneurysm	0.000788	0.00165	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—LRP1—abdominal aortic aneurysm	0.000788	0.00165	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—AGT—abdominal aortic aneurysm	0.000777	0.00163	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—AGTR1—abdominal aortic aneurysm	0.00076	0.00159	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NCF1—abdominal aortic aneurysm	0.000759	0.00159	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NCF1—abdominal aortic aneurysm	0.000753	0.00158	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—CCL2—abdominal aortic aneurysm	0.000745	0.00156	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—P2RY12—abdominal aortic aneurysm	0.000737	0.00155	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NCF1—abdominal aortic aneurysm	0.000737	0.00155	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—AGTR1—abdominal aortic aneurysm	0.000726	0.00152	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—AGT—abdominal aortic aneurysm	0.000726	0.00152	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—AGT—abdominal aortic aneurysm	0.00072	0.00151	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—AGT—abdominal aortic aneurysm	0.000705	0.00148	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—MMP9—abdominal aortic aneurysm	0.000685	0.00143	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—LRP1—abdominal aortic aneurysm	0.000685	0.00143	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—NFKB1—abdominal aortic aneurysm	0.000677	0.00142	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—MMP3—abdominal aortic aneurysm	0.000677	0.00142	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—AGTR1—abdominal aortic aneurysm	0.00066	0.00138	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—P2RY12—abdominal aortic aneurysm	0.00064	0.00134	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—AGTR1—abdominal aortic aneurysm	0.000609	0.00128	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AGTR1—abdominal aortic aneurysm	0.000605	0.00127	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—CCL2—abdominal aortic aneurysm	0.000598	0.00125	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—LDLR—abdominal aortic aneurysm	0.000598	0.00125	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—CCL2—abdominal aortic aneurysm	0.000593	0.00124	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AGTR1—abdominal aortic aneurysm	0.000592	0.00124	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—AGT—abdominal aortic aneurysm	0.000589	0.00123	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—MMP3—abdominal aortic aneurysm	0.000588	0.00123	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—CCL2—abdominal aortic aneurysm	0.000581	0.00122	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NCF1—abdominal aortic aneurysm	0.000559	0.00117	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MMP3—abdominal aortic aneurysm	0.000543	0.00114	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MMP3—abdominal aortic aneurysm	0.000539	0.00113	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—AGT—abdominal aortic aneurysm	0.000535	0.00112	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MMP3—abdominal aortic aneurysm	0.000528	0.00111	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—LDLR—abdominal aortic aneurysm	0.000519	0.00109	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—AGT—abdominal aortic aneurysm	0.000511	0.00107	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NCF1—abdominal aortic aneurysm	0.000485	0.00102	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—AGT—abdominal aortic aneurysm	0.000475	0.000995	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—abdominal aortic aneurysm	0.000465	0.000975	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—AGT—abdominal aortic aneurysm	0.000464	0.000973	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—AAAS—abdominal aortic aneurysm	0.000458	0.00096	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AGTR1—abdominal aortic aneurysm	0.000449	0.00094	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CCL2—abdominal aortic aneurysm	0.00044	0.000923	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—AGT—abdominal aortic aneurysm	0.000429	0.000899	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AGT—abdominal aortic aneurysm	0.000426	0.000892	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—AAAS—abdominal aortic aneurysm	0.000421	0.000883	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—APOE—abdominal aortic aneurysm	0.00042	0.00088	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—APOE—abdominal aortic aneurysm	0.000417	0.000874	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AGT—abdominal aortic aneurysm	0.000417	0.000873	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—APOE—abdominal aortic aneurysm	0.000408	0.000856	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MMP3—abdominal aortic aneurysm	0.0004	0.000838	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—LDLR—abdominal aortic aneurysm	0.0004	0.000838	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AGTR1—abdominal aortic aneurysm	0.00039	0.000817	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CCL2—abdominal aortic aneurysm	0.000382	0.000801	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—LDLR—abdominal aortic aneurysm	0.000368	0.000771	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCL2—abdominal aortic aneurysm	0.000353	0.00074	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCL2—abdominal aortic aneurysm	0.00035	0.000734	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MMP3—abdominal aortic aneurysm	0.000347	0.000728	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCL2—abdominal aortic aneurysm	0.000343	0.000719	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SERPINE1—abdominal aortic aneurysm	0.00033	0.000691	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SERPINE1—abdominal aortic aneurysm	0.000327	0.000686	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SERPINE1—abdominal aortic aneurysm	0.00032	0.000671	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—abdominal aortic aneurysm	0.000319	0.000668	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AGT—abdominal aortic aneurysm	0.000316	0.000662	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—APOE—abdominal aortic aneurysm	0.000309	0.000648	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AAAS—abdominal aortic aneurysm	0.000275	0.000577	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AGT—abdominal aortic aneurysm	0.000274	0.000575	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—APOE—abdominal aortic aneurysm	0.000269	0.000563	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCL2—abdominal aortic aneurysm	0.00026	0.000545	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MMP9—abdominal aortic aneurysm	0.000253	0.000529	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MMP9—abdominal aortic aneurysm	0.000251	0.000525	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NFKB1—abdominal aortic aneurysm	0.00025	0.000524	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NFKB1—abdominal aortic aneurysm	0.000248	0.00052	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MMP9—abdominal aortic aneurysm	0.000245	0.000514	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SERPINE1—abdominal aortic aneurysm	0.000243	0.000509	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NFKB1—abdominal aortic aneurysm	0.000243	0.000509	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—LDLR—abdominal aortic aneurysm	0.000241	0.000504	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCL2—abdominal aortic aneurysm	0.000226	0.000473	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—AGT—abdominal aortic aneurysm	0.000211	0.000443	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SERPINE1—abdominal aortic aneurysm	0.000211	0.000442	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—APOE—abdominal aortic aneurysm	0.000207	0.000434	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—AGT—abdominal aortic aneurysm	0.000194	0.000407	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—APOE—abdominal aortic aneurysm	0.00019	0.000399	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MMP9—abdominal aortic aneurysm	0.000186	0.00039	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NFKB1—abdominal aortic aneurysm	0.000184	0.000386	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MMP9—abdominal aortic aneurysm	0.000162	0.000338	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NFKB1—abdominal aortic aneurysm	0.00016	0.000335	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTGS2—abdominal aortic aneurysm	0.000142	0.000297	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTGS2—abdominal aortic aneurysm	0.000131	0.000274	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AGT—abdominal aortic aneurysm	0.000127	0.000266	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—APOE—abdominal aortic aneurysm	0.000125	0.000261	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTGS2—abdominal aortic aneurysm	8.53e-05	0.000179	CbGpPWpGaD
